ArticleCase reports in women's health2025
Challenges in managing cervical cancer in pregnancy: Three case reports.
Article in Case reports in women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer in pregnancy is a rare but increasingly recognised condition, affecting approximately 0.1-12.0 per 10,000 pregnancies annually. Symptoms such as vaginal bleeding, discharge, dyspareunia, and pelvic pain may overlap with normal pregnancy-related changes, often leading to delayed diagnosis. Speculum and bimanual examination is essential in pregnant women presenting with vaginal bleeding. Urgent colposcopy referral (for example, in the UK through the two-week wait pathway) is essential. Management strategies depend on cancer stage, gestational age, and patient preferences. Options include pregnancy termination with immediate treatment or consideration of neoadjuvant chemotherapy during pregnancy in women who wish to postpone definitive therapies until after delivery. Pelvic lymphadenectomy for staging is considered safe prior to 22 weeks of gestation. Neoadjuvant chemotherapy is contraindicated in the first trimester but may be administered safely later in pregnancy. Serial magnetic resonance imaging is valuable for monitoring tumour progression and informing treatment plans. This case series highlights the clinical and ethical complexities in managing cervical cancer in pregnancy and underscores the importance of specialist, multidisciplinary, and individualised care. Further research is necessary to develop standardised, evidence-based guidelines for this challenging clinical scenario.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.